2026 Interim report
Filed with HKEX · Stock code 2162 · · 69 pages · English
Summary by 6ix AI
The report highlights a substantial increase in revenue and profit, with the company transitioning from a loss to profitability, primarily driven by successful sales of its core product, Kangyueda. Additionally, the report discusses the company's dual-engine growth model, which has enhanced its market presence both domestically and internationally. Keymed's product pipeline continues to expand, with multiple drug candidates in various stages of clinical trials, reflecting its commitment to innovation in the biotechnology sector.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Keymed Biosciences, Inc. on 6ix
Earlier from Keymed Biosciences
- Keymed Biosciences Announces 2026 H1 Results and Business Updates
- Keymed Biosciences Announces 2025 Annual Results and Business Updates
- Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum
- Keymed Biosciences Announces The Latest Clinical Trial Results Of Cm336 Published In The New England Journal Of Medicine
- Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors
Later from Keymed Biosciences
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Inside information announcement-(1) update on product revenue for the first three quarters of 2026 and (2) national medical products administration approves the new indication marketing application for Stapokibart for the treatment of moderate-to-severe atopic dermatitis in adolescents
- Voluntary announcement - share purchase pursuant to the 2022 restricted share unit scheme
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Follow Keymed Biosciences into a list and get an email when it puts out news.
Follow Keymed Biosciences